Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2000
03/23/2000CA2343920A1 Aerosolizable particles resistant to hygroscopic growth
03/23/2000CA2343838A1 Atp synthase subunit homolog
03/23/2000CA2343760A1 Orally administered controlled drug delivery system providing temporal and spatial control
03/23/2000CA2343578A1 Human serine/threonine protein kinases
03/23/2000CA2343574A1 Metabotropic gaba receptor complex issued from the central nervous system
03/23/2000CA2343354A1 Inhibitor of brn-3b and its use for the treatment of breast and ovarian cancer
03/23/2000CA2343223A1 Anti-inflammatory and antimicrobial uses for bioactive glass compositions
03/23/2000CA2343220A1 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
03/23/2000CA2343133A1 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
03/23/2000CA2342965A1 Leptin induced genes
03/23/2000CA2342833A1 Human gpcr proteins
03/23/2000CA2342398A1 Moraxella catarrhalis basb034 polypeptides and uses thereof
03/23/2000CA2342301A1 Human cell junction pdz protein
03/23/2000CA2342223A1 A new composition
03/23/2000CA2341683A1 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto
03/23/2000CA2341155A1 Genes encoding for the human and murine death inducer-obliterator-1
03/23/2000CA2340586A1 T-type calcium channel
03/22/2000EP0987552A2 Diarylsulfonylurea binding proteins
03/22/2000EP0987275A2 Molecules that home to a selected organ or tissue in vivo and methods of identifying same
03/22/2000EP0987025A1 Pharmaceitical composition or composition package containing a pyrimidine nucleoside analogue and a purine nucleoside analogue
03/22/2000EP0986646A1 Ubiquitin conjugation proteins
03/22/2000EP0986400A1 Integrin ligand, human mindin
03/22/2000EP0986397A1 Use of leptin antagonists for the treatment of diabet
03/22/2000EP0986396A1 Prion protein modulator factor (ppmf) and prion resistant animals
03/22/2000EP0986387A1 FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
03/22/2000EP0986385A1 Antagonists of gonadotropin releasing hormone
03/22/2000EP0986376A1 COMPOSITIONS FOR TREATING AND PREVENTING ARTERIAL THROMBOSIS AND USE OF A FACTOR Xa INHIBITOR ON ITS OWN AND/OR COMBINED WITH A PLATELET ANTIAGGREGATING AGENT
03/22/2000EP0986375A2 Use of mkc-442 in combination with other antiviral agents
03/22/2000EP0986373A1 Drug targeting system, method of its preparation and its use
03/22/2000EP0986372A1 Vesicular complexes and methods of making and using the same
03/22/2000EP0986309A1 Uses of oil bodies
03/22/2000EP0986302A1 A method of treating cancer
03/22/2000EP0665749B1 Composition for the treatment of parkinson's disease
03/22/2000CN1248177A Coated particles, method of making and using
03/22/2000CN1248170A Preparation for treatment of metabolic syndrome containing human growth hormone in combination with cortisol synthesis inhibitor
03/22/2000CN1248169A Compositions for treatment of ARDS or IRDS containing 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamide and lung surfactant
03/22/2000CN1248167A Administration of injectable antibiotic in ear of animal
03/22/2000CN1248162A Topical pharmaceutical composition comprising cholinergic agent or calcium channel blocker
03/21/2000US6040434 Screening for compound which reduces or prevents formation of 3'-amino-3'-deoxythymidine from 3'-azido-3'-deoxythymidine (azt); side effect reduction in mammals receiving viricidal therapy
03/21/2000US6040346 Use of L-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral drugs
03/21/2000US6040340 Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
03/21/2000US6040336 Treating bacterially induced meningitis
03/21/2000US6040312 Formulations and methods of reducing toxicity of antineoplastic agents
03/21/2000US6040311 Treating bone disorders for preventing osteoporosis or inhibiting bone resorption in a mammal; treating tumor growth in a mammal
03/21/2000US6040304 Formulations and methods of reducing toxicity of antineoplastic agents
03/21/2000US6040294 The compounds have either a sulfhydryl moiety or are reducible disulfides; reducing the side effect of cancer drug
03/21/2000US6040181 Regulation of bcl-2 gene expression
03/21/2000US6040163 Amino acid sequence which couples asparagine to transfer rna; for screening bacteriostats and bactericides
03/21/2000US6040162 Amino acid sequence which couples histidine to transfer rna; for screening bacteriostats and bactericides
03/21/2000US6040145 Potentiation of the immune response
03/21/2000US6039978 Dietary food enhancement agent
03/21/2000US6039974 Drugs of multilayer tablets
03/21/2000US6039959 Treatment and diagnosis of infections due to helicobacter pylori
03/21/2000US6039955 Plant extracts as antiinflammatory agents
03/21/2000US6039945 Administering purified prothrombinase factor to humans
03/16/2000WO2000014275A2 Two-colour differential display, used as a method for detecting regulated genes
03/16/2000WO2000014231A1 Lim domain protein homolog
03/16/2000WO2000014222A2 GABAB RECEPTOR SUBTYPES GABAB-R1c AND GABAB-R2 AND HETERODIMERS THEREOF
03/16/2000WO2000014220A1 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus
03/16/2000WO2000014200A2 Essential bacterial genes and their use
03/16/2000WO2000014115A1 Mc4-r as target for the identification of compounds used to treat drug addiction
03/16/2000WO2000014114A1 Peptide fragments of cholera toxin b or enterotoxin b as vaccine adjuvants
03/16/2000WO2000014065A1 Kappa agonist compounds and pharmaceutical formulations thereof
03/16/2000WO2000014063A1 Therapeutic compounds and methods
03/16/2000WO2000013712A2 Methods and compositions for the prevention or treatment of cancer
03/16/2000WO2000013709A2 Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
03/16/2000WO2000013708A1 Methods for treating or preventing viral infections and associated diseases
03/16/2000WO2000013707A1 Preventives/remedies for multiple organ failure
03/16/2000WO2000013706A1 Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
03/16/2000WO2000013703A2 Methods of treating hypertension and compositions for use therein
03/16/2000WO2000013702A2 Use of an angiogenic factor for the treatment of microvascular angiopathies
03/16/2000WO2000013698A1 Drug screening and diagnosis based on paracrine tubular renin-angiotensin system
03/16/2000WO2000013694A1 Gcp
03/16/2000WO2000013689A1 Methods and compositions for increasing intestinal absorption of fats
03/16/2000WO2000013684A2 Pharmaceutical composition and method for treatment of inflammation
03/16/2000WO2000013677A1 Nanogel networks and biological agent composition thereof
03/16/2000WO2000013667A1 Lipstatin derivative-soluble fiber tablets
03/16/2000WO2000013664A1 Drug preparations for treating sexual dysfunction
03/16/2000WO2000013650A2 Neuroprotection
03/16/2000WO2000006694A3 Compound and method for the prevention and/or the treatment of allergy
03/16/2000WO2000002582A3 Treatment of celiac disease with interleukin-15 antagonists
03/16/2000WO1999063932A9 Multibinding agents that modulate the 5-ht transporter
03/16/2000WO1999061471A3 Human transmembrane proteins
03/16/2000CA2343522A1 Methods for treating or preventing viral infections and associated diseases
03/16/2000CA2343214A1 Neuroprotection
03/16/2000CA2342994A1 Kappa agonist compounds and pharmaceutical formulations thereof
03/16/2000CA2342921A1 Drug screening and diagnosis based on paracrine tubular renin-angiotensin system
03/16/2000CA2342858A1 Method of screening compounds useful in the treatment of a desease caused by or exacerbated by mpv
03/16/2000CA2342800A1 Nanogel networks and biological agent composition thereof
03/16/2000CA2342796A1 Preventives/remedies for multiple organ failure
03/16/2000CA2342769A1 Drug preparations for treating sexual dysfunction
03/16/2000CA2342625A1 Lipstatin derivative-soluble fiber tablets
03/16/2000CA2342349A1 Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
03/16/2000CA2342280A1 Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
03/16/2000CA2341782A1 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus
03/16/2000CA2341752A1 Methods and compositions for the prevention or treatment of cancer
03/16/2000CA2341325A1 Method of stimulating prosaposin receptor activity
03/16/2000CA2341302A1 Lim domain protein homolog
03/16/2000CA2340323A1 Mc4-r as target for the identification of compounds used to treat drug addiction
03/16/2000CA2338384A1 Peptide fragments of cholera toxin b or enterotoxin b as vaccine adjuvants
1 ... 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 ... 1151